Contrarian Trader/ Political Commentator / Financial Markets Fuckery Please follow and be part of the conversations Much Appreciated.
Joined May 2020
- Tweets7.6K
- Following480
- Followers437
- Likes10.3K
$QQQ Bullish divergence. BUYY
The bottom oscillator dipped into oversold territory on the initial drop, but on the lower price push, the RSI formed a Higher Low and began curling back up out of the oversold band.
AHAHAHA and people want to short the stock market into this?
These retards are going to make the money printer go BRRRRRRRRRRRRRR!!!!!
I am buying this selloff here
$QQQ $SPY
$ALB just put in the the biggest volume candle since Dec 2025.
The earnings were solid and it’s up over 3% in after hours
Tomorrow it’s going to open over this downward trendline that’s been in play since last year.
The stock is down over 60% and has an average price target of $150. That’s a 50% upside.
With the democrats controlling the house and the senate and soon the presidency.
Clean energy is the new momentum play.
Get in while you can
$QQQ $SPY $ENPH $FSLR
Jesus!
My heart hurts thinking of those two kids so afraid and confused in their last moments. At least their deaths were painless. So tragic
RIP
BREAKING: Texas tech entrepreneur Adam Robinson, 44, his wife Helen, their two young children, their nanny and two friends were among the nine people killed when a Learjet 60 crashed in Florida while traveling from Austin to the Bahamas, according to TMZ.
The crew members were identified as pilot Jeff Gregory, 55, and co-pilot Nathalia Gadelha Filgueiras, 20. The cause of the crash remains under investigation.
📸: @TMZ
This market it ridiculous.
They punish Amazon for spending too much on CapEx but they also punish the companies that are receiving that CapEx.
wtf?
This is a buy the dip opportunity in Hardware names.
AI is incredible and it’s not slowing down.
The amount of productivity we get in our business from AI is insane.
If Claude raided their price by 100% tomorrow, I would pay it and so would most people.
You really think people are going to stop using Chatbots now that everyone knows what it is?
$QQQ $SPY $AMZN
Why the fuck would you short it when the stock has already dropped like 80%
If I had all this information, even if I knew it was true, I would still not short into a fucking hole like this.
Clearly, who is whoever is running this fund is absolutely retarded
$CBRS $QQQ $SPY
Today is a buy the dip opportunity in Tech.
I feel like we are reaching the peak escalation in this Iran war.
It’s not just the US, the entire world is suffering.
China is suffering, Russia is suffering, US is suffering, Europe is suffering.
It is in everyone’s best interest to get this war over with.
Iran is holding out until the midterms to inflict their pain on Trump.
Post that, they HAVE to make a deal.
By next year a lot of the oil leaving the gulf will be diverted to other routes and pipelines.
The more time goes by. The less leverage Iran has.
They will make a deal.
Couple that will buy back window opening, I think we see a tech rally into year end.
$QQQ $SPY $NVDA $MSFT $GOOG
What did we learn about $MRNA from the $MRK earnings?
Yes, the 0.58 RFS looks shiny on a slide deck. But go look at the actual regulatory disclosures: Overall Survival (OS) is completely immature.
The FDA has been ruthless lately about surrogate endpoints. If regulators look at this and say "cool story, but we’re throwing you into Accelerated Approval until people actually live longer," the entire bull thesis takes a reality check:
Insurance companies are going to fight this tooth and nail. You think payers are going to happily shell out an insane, personalized-mRNA price tag without hard proof that patients are actually surviving longer?
Expect brutal prior auths and red tape.
Accelerated approval is a ticking clock. If they get stamped with conditional approval and that OS trend flattens out in a couple of years (which happens constantly in oncology), both MRK andMRNA are holding a massive regulatory bag.
The supply chain is already a logistical nightmare. Moderna has to sequence, synthesize, and cryo-ship a custom batch for every single patient inside a 6-week window. Doing that high-wire act for a drug with a conditional asterisk next to its name is insane operational overhead.
Surrogate numbers pump stock prices on day one, but survival curves are what actually build multi-billion dollar drugs. Until we see real, mature OS separation, this is priced for pure perfection that hasn’t actually been proven yet.
And even if you assume the absolute best-case commercial scenario, the math still doesn't justify the hype:
Under the 50/50 partnership, the most amount of revenue share Moderna can realistically pull in is ~$2.5B to $2.7B per year at peak (assuming a massive ~$5B to $5.5B total product run across high-risk adjuvant melanoma).
Because this isn't an off-the-shelf vaccine where you print batches for pennies, custom sequencing, synthetic mRNA runs, and cold-chain logistics eat into the margins:
Gross Margins: Even with automated cleanrooms, expect gross margins capped around 60% to 65% after factoring in direct sequencing, specialized reagents, and individualized batch handling.
Operating Margins: After joint SG&A, oncology field force allocation, and commercial distribution costs are billed against the collaboration, operating margins will land closer to 35% to 40%.
That leaves Moderna clearing around ~$900M to $1.1B in net operating profit annually. After standard corporate taxes (~15–20%) spread across their ~385M diluted share count, intismeran is only adding around $2.00 to $2.40 in EPS to their earnings—and that’s years down the road at full peak penetration.
Moderna loses $8-9% per share right now. So that mean in 2 years they will still be losing 5-6 per share 🤮🤮
Sell.
$MRK $QQQ $SPY $LLY $JNJ $XLV $AMGN